GSK 2194069

Key Product Details

Product Description

GSK 2194069 is a potent human fatty acid synthase (hFASN) inhibitor (IC₅₀ = 7.7 nM); inhibits hFAS β-ketoacyl reductase activity. Inhibits lipid synthesis and attenuates proliferation of A549 non-small-cell lung cancer cells (EC₅₀ = 15 nM) in vitro. GSK 2194069 also inhibits infection by SARS-CoV-2 (EC₅₀ = 0.9 nM) in vitro.

Product Specifications for GSK 2194069

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GSK 2194069

The following data is based on the product molecular weight 428.48.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.33 mL	11.67 mL	23.34 mL
5 mM	0.47 mL	2.33 mL	4.67 mL
10 mM	0.23 mL	1.17 mL	2.33 mL
50 mM	0.05 mL	0.23 mL	0.47 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 13 publications citing the usage of this product.

• Chu Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat.Metab. 2021 PMID: 34580494
• Hardwicke A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nat.Chem.Biol. 2014 PMID: 25086508

Product Documents for GSK 2194069